Teladoc | Behavioral Change and Weight Management-Pharmacological Agents for Diabetes & Obesity Infographic

Pharmacological Agents for Diabetes & Obesity Infographic

Pdf Summary

This document is a visual guide to the guidelines for pharmacologic agents used in the treatment of diabetes and obesity. It references the recommendations from the American Diabetes Association's Standards of Care in Diabetes for 2023. The document highlights the benefits of using incretins, a type of medication, for managing type 2 diabetes. It states that incretins can delay the progression from prediabetes to type 2 diabetes, improve glycemia, reduce the need for glucose-lowering medications, and promote sustained diabetes remission for at least two years. Incretins are also helpful in achieving and maintaining meaningful weight loss and reducing obesity-related health risks.<br /><br />The document emphasizes the importance of obesity management in treating type 2 diabetes. It mentions different treatment options available, including intensive behavioral counseling, obesity pharmacotherapy, and bariatric surgery. It also provides guidelines for choosing glucose-lowering medications for individuals with type 2 diabetes and overweight or obesity. The guidelines recommend considering weight when choosing medications and minimizing medications that are associated with weight gain. Obesity pharmacotherapy can be effective as an adjunct to nutrition, physical activity, and behavioral counseling for selected individuals with type 2 diabetes and a BMI of 27 kg/m2 or higher.<br /><br />The document categorizes various glucose-lowering medications based on their weight loss efficacy. It suggests considering medications such as exenatide, lixisenatide, SGLT2 inhibitors, DPP-4 inhibitors, metformin, semaglutide, tirzepatide, dulaglutide, and liraglutide for individuals with type 2 diabetes and overweight or obesity.<br /><br />Overall, the document provides a summary of the guidelines for using pharmacologic agents in the treatment of diabetes and obesity, with a focus on the benefits of incretins and the importance of obesity management in managing type 2 diabetes.

Keywords

pharmacologic agents

diabetes treatment

obesity treatment

American Diabetes Association

incretins

type 2 diabetes management

glucose-lowering medications

obesity management guidelines

weight loss efficacy

obesity pharmacotherapy